[1] MIRO O,PEACOCK F W,MCMURRAY J J,et al.European Society of Cardiology-Acute Cardiovascular Care Association position paper on safe discharge of acute heart failure patients from the emergency department[J].Eur Heart J Acute Cardiovasc Care,2017,6(4):311-320.
[2] JANUZZI J J,FELKER G M.Surfing the biomarker tsunami at JACC:heart failure[J].JACC Heart Fail,2013,1(3):213-215.
[3] VAN KIMMENADE R R,JANUZZI J J.Emerging biomarkers in heart failure[J].Clin Chem,2012,58(1):127-138.
[4] OREMUS M,DON-WAUCHOPE A,MCKELVIE R,et al.BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure[J].Heart Fail Rev,2014,19(4):471-505.
[5] JANUZZI J L,MEBAZAA A,DI SOMMA S.ST2 and prognosis in acutely decompensated heart failure:the International ST2 Consensus Panel[J].Am J Cardiol,2015,115(7 Suppl):26B-31B.
[6] CLYDE Y,MARIELL J,BIYKEM B,et al.2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure:an update of the 2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology Foundation/American Heart Association Task Force on clinical practice guidelines and the heart failure society of America[J].Circulation,2016,134(13):e282-93.
[7] MUKHERJI A,ANSARI U,BORGGREFE M,et al.Clinically relevant biomarkers in acute heart failure:an update[J].Curr Pharm Biotechnol,2017,18(6):482-490.
[8] PASCUAL-FIGAL D A,JANUZZI J L.The biology of ST2:the International ST2 Consensus Panel[J].Am J Cardiol,2015,115(7 Suppl):3B-7B.
[9] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-122.
[10] ROSSANO J W.Clinical management of patients with acute heart failure[J].Cardiol Young,2015,25(Suppl 2):67-73.
[11] FARMAKIS D,PARISSIS J,LEKAKIS J,et al.Acute heart failure:Epidemiology,risk factors,and prevention[J].Rev Esp Cardiol (Engl Ed),2015,68(3):245-248.
[12] WEINBERG E O,SHIMPO M,DE KEULENAER G W,et al.Expression and regulation of ST2,an interleukin-1 receptor family member,in cardiomyocytes and myocardial infarction[J].Circulation,2002,106(23):2961-2966.
[13] JANUZZI J J,PEACOCK W F,MAISEL A S,et al.Measurement of the interleukin family member ST2 in patients with acute dyspnea:results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study[J].J Am Coll Cardiol,2007,50(7):607-613.
[14] OSHIKAWA K,KUROIWA K,TAGO K,et al.Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation[J].Am J Respir Crit Care Med,2001,164(2):277-281.
[15] WU A H,WIANS F,JAFFE A.Biological variation of galectin-3 and soluble ST2 for chronic heart failure:implication on interpretation of test results[J].Am Heart J,2013,165(6):995-999.
[16] BOISOT S,BEEDE J,ISAKSON S,et al.Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure[J].J Card Fail,2008,14(9):732-738.
[17] PFISTER R,TAN D,THEKKANAL J,et al.Predictors of elevated NT-pro-BNP in cardiovascular patients without acute heart failure[J].Int J Cardiol,2009,131(2):277-280.
[18] MUELLER T,DIEPLINGER B,GEGENHUBER A,et al.Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure[J].Clin Chem,2008,54(4):752-756.
[19] REHMAN S U,MUELLER T,JANUZZI J J.Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure[J].J Am Coll Cardiol,2008,52(18):1458-1465. |